Daridorexant

Product Name: Daridorexant

Form: HCl Salt

CAS No: 1505484-82-1

Molar Mass: 450.93

Chemical Formula: C23H23ClN6O2

Synonyms: Nemorexant, ACT541468

Storage: Store at -20℃

Target: orexin receptor

Application:

Daridorexant (CAS: 1505484-82-1) is a dual orexin receptor antagonist (DORA) used in the treatment of insomnia. It functions by selectively blocking the activity of orexin receptors in the brain, specifically targeting both orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). Orexin, also known as hypocretin, is a neuropeptide involved in regulating wakefulness and arousal. By inhibiting orexin signaling, daridorexant promotes sleep initiation and maintenance without causing significant sedation or next-day residual effects commonly associated with traditional sedative-hypnotic medications. In pharmaceutical chemistry, daridorexant's targeted action on orexin receptors represents a novel approach to treating insomnia, offering a more specific and potentially safer alternative to conventional sleep aids. Its application underscores its importance in improving sleep quality and overall well-being for individuals with insomnia. Additionally, ongoing research explores daridorexant's potential in other sleep-related disorders and its role in combination therapies, demonstrating its versatility in sleep medicine and neuropharmacology.

Current Research:

Daridorexant is a novel, dual orexin receptor antagonist (DORA) developed for the treatment of insomnia in adults. Insomnia is a common sleep disorder characterized by difficulty falling asleep or staying asleep, often resulting in daytime impairment or distress. Daridorexant selectively targets the orexin system, which is involved in the regulation of wakefulness. By blocking the orexin receptors, Daridorexant effectively promotes sleep without the risks of addiction or significant side effects commonly associated with other sleep aids, such as benzodiazepines. It represents a promising therapeutic option for patients seeking a safe and effective solution for chronic insomnia.

Mechanism of Action
Daridorexant exerts its therapeutic effects by antagonizing both orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). Orexins are neuropeptides that play a crucial role in the regulation of the sleep-wake cycle, particularly promoting wakefulness and arousal. By inhibiting the binding of orexins to their receptors, Daridorexant suppresses the signaling pathways that maintain wakefulness, leading to the promotion of sleep. This mechanism contrasts with that of traditional sleep medications, which typically enhance the action of GABA (gamma-aminobutyric acid), a neurotransmitter that has sedative effects. By specifically targeting the orexin system, Daridorexant offers a more selective approach to managing insomnia, potentially reducing the risk of tolerance, dependence, and daytime sedation.

Indications and Uses
Daridorexant is primarily indicated for the treatment of insomnia in adults, particularly in individuals who experience difficulties in both sleep initiation and sleep maintenance. The drug is effective in improving sleep quality, enhancing sleep duration, and reducing sleep onset latency. Unlike many traditional hypnotics, Daridorexant is also associated with a lower risk of residual daytime sleepiness, which is a common concern with older sleep aids. Daridorexant is prescribed as a once-daily oral dose, typically taken before bedtime. It is recommended for patients who have not responded adequately to non-pharmacological treatments for insomnia, such as cognitive behavioral therapy for insomnia (CBT-I).

Efficacy and Clinical Benefits
Clinical studies have demonstrated that Daridorexant is highly effective in treating insomnia. In pivotal trials, Daridorexant significantly improved both sleep onset and sleep maintenance compared to placebo. Patients taking Daridorexant reported faster sleep onset, longer sleep duration, and higher quality of sleep, with sustained benefits over the course of treatment. One of the key advantages of Daridorexant is its ability to improve sleep without causing significant next-day sedation, a side effect often seen with other sleep medications like benzodiazepines or non-benzodiazepine receptor agonists (e.g., zolpidem). The drug has also been shown to have a minimal impact on cognitive function, allowing patients to experience restorative sleep without impairment of daytime functioning.

Safety and Tolerability
Daridorexant is generally well tolerated, with a safety profile that is favorable compared to traditional hypnotics. The most common side effects reported during clinical trials are mild and include headaches, somnolence, and nasopharyngitis. These side effects are typically transient and resolve with continued use of the medication. Importantly, Daridorexant has a low risk of abuse, dependence, and tolerance, making it a safer long-term treatment option for patients with chronic insomnia. Additionally, Daridorexant does not significantly impair cognitive or motor performance, which reduces the risk of accidents or falls, a major concern with other sedative drugs. However, like all sleep medications, it should be used with caution in individuals with a history of psychiatric disorders, as it may exacerbate certain conditions in sensitive patients.

Advantages and Limitations
One of the primary advantages of Daridorexant is its novel mechanism of action as a dual orexin receptor antagonist, which offers a more targeted approach to managing insomnia compared to other sleep aids. This selectivity results in fewer side effects, such as daytime sedation and cognitive impairment, which are often problematic with traditional hypnotics. Additionally, Daridorexant has a low risk of tolerance and dependence, making it a preferable choice for long-term use. However, its use is limited by the need for careful monitoring, especially in patients with underlying medical conditions. Although Daridorexant is effective for most patients, it may not work for everyone, and some patients may require alternative therapies or adjunctive treatments to achieve optimal results.

Future Directions
Ongoing research is focused on exploring the broader potential of Daridorexant for other sleep disorders, such as sleep maintenance insomnia and circadian rhythm disorders. Studies are also investigating the use of Daridorexant in combination with other treatments for insomnia, such as cognitive behavioral therapy, to enhance its efficacy and provide a more comprehensive treatment approach. There is also interest in exploring Daridorexant’s long-term safety profile and effectiveness, particularly in diverse patient populations, including those with comorbid conditions such as depression or anxiety disorders. Additionally, newer formulations or dosing strategies may be developed to improve patient convenience and adherence to therapy.

Reference:

Dauvilliers, Y., Zammit, G., Fietze, I., Mayleben, D., Seboek Kinter, D., Pain, S., & Hedner, J. (2020). Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Annals of neurology, 87(3), 347-356.

Fernandes, M., Placidi, F., Mercuri, N. B., & Liguori, C. (2024). Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study. Neurological Sciences, 1-6.